The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for blockbuster treatments and impressive returns is clear, the connected risks are also notable. Many of these